3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Primary Myelofibrosis
13
Myeloproliferative Disorders
9
Leukemia, Myeloid, Acute
8
Thrombocythemia, Essential
6
Polycythemia Vera
6
Myelodysplastic Syndromes
5
Leukemia
5
Lymphoma, T-Cell
4
Recurrence
3
Neoplasms
3
Graft vs Host Disease
3
Myelodysplastic-Myeloproliferative Diseases
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma
2
Leukemia, Prolymphocytic, T-Cell
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hematologic Neoplasms
2
Uveal Melanoma
1
Thalassemia
1
Targeted Therapy
1
Prostatic Neoplasms
1
Preleukemia
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Neoplasms by Histologic Type
1
Mycosis Fungoides
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Interventions
peginterferon alfa-2b
1
liposomal doxorubicin
1
dolutegravir
1
belinostat
1
Zidovudine
1
Tenofovir
1
Taxes
1
Paclitaxel
1
Lomustine
1
Irinotecan
1
Introns
1
Gemcitabine
1
Doxorubicin
1
Cyclophosphamide
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Leukemia-Lymphoma, Adult T-Cell
×
ruxolitinib
×
90 days
×
Clear all
No trials found.